Hendley & Co. Inc. Has $2.53 Million Holdings in Merck & Co., Inc. (MRK)

Share on StockTwits

Hendley & Co. Inc. trimmed its position in shares of Merck & Co., Inc. (NYSE:MRK) by 51.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 33,063 shares of the company’s stock after selling 34,781 shares during the period. Hendley & Co. Inc.’s holdings in Merck & Co., Inc. were worth $2,526,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. Contravisory Investment Management Inc. boosted its stake in shares of Merck & Co., Inc. by 186.4% in the 4th quarter. Contravisory Investment Management Inc. now owns 653 shares of the company’s stock valued at $50,000 after purchasing an additional 425 shares in the last quarter. Arlington Partners LLC boosted its stake in shares of Merck & Co., Inc. by 93.5% in the 4th quarter. Arlington Partners LLC now owns 828 shares of the company’s stock valued at $63,000 after purchasing an additional 400 shares in the last quarter. Advisors Preferred LLC acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at approximately $66,000. Lenox Wealth Advisors LLC boosted its stake in shares of Merck & Co., Inc. by 86.5% in the 3rd quarter. Lenox Wealth Advisors LLC now owns 1,656 shares of the company’s stock valued at $117,000 after purchasing an additional 768 shares in the last quarter. Finally, WESPAC Advisors SoCal LLC acquired a new stake in shares of Merck & Co., Inc. in the 3rd quarter valued at approximately $118,000. Hedge funds and other institutional investors own 72.43% of the company’s stock.

A number of equities research analysts have recently weighed in on MRK shares. BMO Capital Markets downgraded shares of Merck & Co., Inc. from an “outperform” rating to a “market perform” rating and set a $80.00 price target on the stock. in a research note on Wednesday, January 23rd. Zacks Investment Research upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $83.00 price target on the stock in a research note on Friday, January 4th. SunTrust Banks raised their price target on shares of Merck & Co., Inc. from $77.00 to $80.00 and gave the company a “buy” rating in a research note on Monday, October 29th. Morgan Stanley set a $81.00 price target on shares of Merck & Co., Inc. and gave the company a “buy” rating in a research note on Thursday, December 20th. Finally, Credit Suisse Group set a $86.00 price target on shares of Merck & Co., Inc. and gave the company a “buy” rating in a research note on Thursday, December 13th. Six equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Merck & Co., Inc. presently has a consensus rating of “Buy” and an average target price of $73.80.

Merck & Co., Inc. stock opened at $79.24 on Wednesday. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.44 and a quick ratio of 1.15. Merck & Co., Inc. has a 52-week low of $52.83 and a 52-week high of $80.19. The company has a market cap of $215.18 billion, a price-to-earnings ratio of 18.26, a PEG ratio of 2.11 and a beta of 0.62.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Friday, February 1st. The company reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.03 by $0.01. Merck & Co., Inc. had a net margin of 14.71% and a return on equity of 35.10%. The firm had revenue of $11 billion during the quarter, compared to analyst estimates of $10.93 billion. During the same quarter last year, the business earned $0.98 EPS. The company’s revenue was up 5.4% compared to the same quarter last year. Analysts forecast that Merck & Co., Inc. will post 4.66 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, April 5th. Shareholders of record on Friday, March 15th will be issued a dividend of $0.55 per share. The ex-dividend date is Thursday, March 14th. This represents a $2.20 annualized dividend and a yield of 2.78%. Merck & Co., Inc.’s payout ratio is 50.69%.

Merck & Co., Inc. announced that its board has authorized a stock repurchase plan on Thursday, October 25th that authorizes the company to repurchase $10.00 billion in shares. This repurchase authorization authorizes the company to buy up to 5.1% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s leadership believes its stock is undervalued.

In other news, Chairman Kenneth C. Frazier sold 135,613 shares of Merck & Co., Inc. stock in a transaction on Tuesday, February 19th. The shares were sold at an average price of $80.03, for a total value of $10,853,108.39. Following the completion of the sale, the chairman now owns 784,863 shares in the company, valued at approximately $62,812,585.89. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Thomas H. Glocer sold 10,000 shares of Merck & Co., Inc. stock in a transaction on Monday, February 4th. The shares were sold at an average price of $75.96, for a total transaction of $759,600.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 616,533 shares of company stock valued at $48,660,563. Company insiders own 0.32% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Hendley & Co. Inc. Has $2.53 Million Holdings in Merck & Co., Inc. (MRK)” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/4165722/hendley-co-inc-has-2-53-million-holdings-in-merck-co-inc-mrk.html.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Featured Story: What economic reports are most valuable to investors?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

GeneNews  Stock Price Up 6.3%
GeneNews Stock Price Up 6.3%
Armadale Capital  Stock Price Down 7.6%
Armadale Capital Stock Price Down 7.6%
Caleres  Price Target Cut to $26.00 by Analysts at Loop Capital
Caleres Price Target Cut to $26.00 by Analysts at Loop Capital
G-III Apparel Group  Price Target Raised to $39.00 at Barclays
G-III Apparel Group Price Target Raised to $39.00 at Barclays
Vuzix  Stock Rating Upgraded by Zacks Investment Research
Vuzix Stock Rating Upgraded by Zacks Investment Research
HANG SENG BK LT/S  Rating Increased to Buy at UBS Group
HANG SENG BK LT/S Rating Increased to Buy at UBS Group


© 2006-2019 Ticker Report